Kovitz Investment Group Partners LLC Purchases Shares of 26,514 Aerovate Therapeutics, Inc. $AVTE

Kovitz Investment Group Partners LLC purchased a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 26,514 shares of the company’s stock, valued at approximately $67,000. Kovitz Investment Group Partners LLC owned about 0.09% of Aerovate Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of AVTE. GTS Securities LLC bought a new stake in Aerovate Therapeutics during the fourth quarter valued at approximately $27,000. PNC Financial Services Group Inc. raised its position in shares of Aerovate Therapeutics by 8,210.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,962 shares of the company’s stock valued at $35,000 after buying an additional 13,794 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Aerovate Therapeutics by 110.7% during the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company’s stock worth $40,000 after acquiring an additional 7,977 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth $52,000. Finally, Rhumbline Advisers increased its stake in Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company’s stock valued at $57,000 after acquiring an additional 9,154 shares during the last quarter.

Aerovate Therapeutics Stock Up 11.5%

NASDAQ AVTE opened at $8.23 on Friday. The stock’s 50-day simple moving average is $8.67 and its two-hundred day simple moving average is $41.71. Aerovate Therapeutics, Inc. has a twelve month low of $56.35 and a twelve month high of $105.00. The company has a market capitalization of $238.55 million, a price-to-earnings ratio of -2.75 and a beta of 0.95.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.